Due to the quality and a low number of trials included, we could not accurately and quantitatively describe the effectiveness of P2Y12 inhibitors on migraine in terms of headache intensity, duration, and frequency and also could not perform subgroup and sensitivity analysis. This evidence concerns the gene P2RY12 and migraine disorder.